# MATINS HEALTHCARE PVT. LTD.

MATINS HEALTHCARE PVT. LTD.

PLOT No.-10, SECTOR-5, IIE, SIDCUL, HARIDWAR
Mfg. Licence No.: 61/UA/SC/P-2006 & 62/UA/2006

**QUALITY CONTROL DEPARTMENT**
**(FINISHED)**
(The Drugs & Cosmetics Act 1940 and the Rules there under)

## CERTIFICATE OF ANALYSIS

| | | | |
|---|---|---|---|
| **Product Name** | HEALMARYL MV 3.3 | **A.R. No.** | FGT-240466 |
| **Generic Name** | Metformin HCl (SR) 500 mg, Glimepiride 3 mg & Voglibose 0.3 mg Tablets | **Batch Size** | 2.0 Lakh Tablets |
| **Batch No.** | MT-240279 | **Sample Qty.** | 100 Tablets |
| **Mfg. Date** | 01/2024 | **Sample received date** | 26/02/2024 |
| **Exp. Date** | 12/2025 | **Date of Release** | 27/02/2024 |

| Sr. No. | TESTS | SPECIFICATIONS | RESULTS |
|---|---|---|---|
| 1 | Description | Yellow/White colour elongated, biconvex, uncoated bilayer tablets | Yellow/White colour elongated, biconvex, uncoated bilayer tablets |
| 2 | Identification: By HPLC | The retention time of the major peak in the chromatogram of the sample solution corresponds to that in the chromatogram of the standard solution, as obtained in the assay. | Complies |
| 3 | Average weight | 850 mg ±5% (807.5 mg to 892.5 mg) | 851.10 mg |
| 4 | Uniformity of weight | ±5% on average weight | Positive deviation= 2.27%<br>Negative deviation= 2.20% |
| 5 | Uniformity of contents | | |
| | For Glimepiride | NLT 85% to NMT 115% | 95.21% to 102.11% |
| | For Voglibose | NLT 85% to NMT 115% | 96.33% to 103.02% |
| 6 | Dissolution | | |
| | For Metformin Hydrochloride (SR)<br>After 1st hour<br>After 3rd hour<br>After 10th hour | <br>NMT 40%<br>45% to 75%<br>NLT 85% | <br>22.17% to 28.14%<br>54.29% to 60.28%<br>95.18% to 99.34% |
| 7 | Assay: Each uncoated bilayer tablet contains: | | |
| | Metformin Hydrochloride IP 500 mg (As Sustained release) | Not Less Than 90% and Not More Than 110% (450.0 mg to 550.0 mg) | 508.05 mg (101.60%) |
| | Glimepiride IP 3 mg | Not Less Than 90% and Not More Than 110% (2.7 mg to 2.2 mg) | 2.95 mg (98.33%) |
| | Voglibose IP 0.3 mg | Not Less Than 90% and Not More Than 110% (0.27 mg to 0.33 mg) | 0.303 mg (101.00%) |

**Remarks:** The product complies as per IHS Specification.

27/02/2024
**Analyzed by**

**Checked by** 27/02/2024

27/02/2024
**Approved by**

Format No.: MHPL/QC-023/F-01/00